Traditional Preparations vs Isolated Compounds and Clinical Products

Why this matters for safety. A result for one of these things cannot be assumed for the others. A case report shows what can happen when ayahuasca, which contains MAO-blocking compounds, meets common cold and allergy medicines: severe serotonin syndrome needing intensive care. [1] The interaction concerns the brew's MAO-blocking compounds, so it is not a finding about DMT alone.

Three different things

• Traditional preparation. A plant or mix of plants used within a particular people's practice, with its own meaning, rules and community. Examples: ayahuasca, iboga as used in the Bwiti tradition, San Pedro in Andean healing traditions.
• Isolated compound. One chemical taken out of the plant, such as DMT, ibogaine, salvinorin A or mescaline.
• Clinical product. A specific product given in a study or by a regulator under defined conditions. Evidence from a trial applies to that product, population and setting only.

An isolated compound is not the cultural practice. A tradition is not clinical evidence. A clinical trial does not validate unregulated products sold under the same plant name. See cultural description vs clinical endorsement.

How the three differ, by example

Why trial results do not transfer

• Different mixtures. Reviews note that brews made with substitute plants or with extracted or synthetic alkaloids are not the traditional preparation. [12][13]
• One trial, one product. The ayahuasca depression trial studied a single dose in 29 people with treatment-resistant depression and followed them for seven days. [14] The ibogaine study of veterans was open-label with 30 people, gave ibogaine with magnesium, and cannot show that ibogaine is safe or effective. [15]
• Variable content. A laboratory study of 14 cactus varieties found large differences in mescaline content, and such a result covers only the specimens tested. [11] NIDA also warns that contaminants or other substances can alter effects. [7]
• Setting. In the Global Ayahuasca Survey, physical adverse effects were linked to non-supervised use and mental health effects were negatively associated with religious settings, but this is an online, self-selected survey and cannot prove cause. [16]
• Few controlled studies. A 2024 review says controlled ayahuasca studies are few, small, single-dose and short. [2]

Respect, consent and ownership

Indigenous-led authors raise concerns about appropriation, patents and the exclusion of Indigenous people from Western psychedelic research. [17] Another paper argues that benefit-sharing is required when isolated compounds derive from traditional knowledge, and that medicalization without respect for Indigenous rights can harm the people and the plants. [18] See Indigenous traditions, ethics and conservation.

Takeaway

There is no universal winner. Preparations, compounds and clinical products answer different questions: cultural meaning, chemistry and tested effects. Check which one a claim is about. For practical comparisons see DMT vs ayahuasca and iboga vs ibogaine, and for the traditional guides see ayahuasca and iboga and Bwiti traditions.